Lessons and tips for designing a machine learning study using EHR data

Jaron Arbet1, Cole Brokamp2,3, Jareen Meinzen-Derr2,3 ⓞ, Katy E. Trinkley4,5 and Heidi M. Spratt6 ⓞ

Abstract

Machine learning (ML) provides the ability to examine massive datasets and uncover patterns within data without relying on a priori assumptions such as specific variable associations, linearity in relationships, or prespecified statistical interactions. However, the application of ML to healthcare data has been met with mixed results, especially when using administrative datasets such as the electronic health record. The black box nature of many ML algorithms contributes to an erroneous assumption that these algorithms can overcome major data issues inherent in large administrative healthcare data. As with other research endeavors, good data and analytic design is crucial to ML-based studies. In this paper, we will provide an overview of common misconceptions for ML, the corresponding truths, and suggestions for incorporating these methods into healthcare research while maintaining a sound study design.

Introduction

The mandate to adopt electronic health records (EHRs) in 2009 under the Health Information Technology for Economic and Clinical Health Act has resulted in widespread electronic collection of health data [1]. With the increase in the use of electronic medical data comes an increase in the amount of healthcare data that are generated. Such EHR data, insurance databases, and other available clinical data have the potential to aid researchers in solving clinical problems. Machine learning (ML) algorithms are quickly rising to the top of the list of tools that can be used to address such problems. However, how to properly use ML methods in the clinical setting is not widely understood. Liu et al. have published an article educating clinicians how to read papers utilizing ML techniques in the medical literature [2]. Nonetheless, understanding the use of ML approaches in healthcare is still needed, especially since precision and accuracy are often key components of solutions to healthcare problems. The intended audience for this manuscript is clinicians and translational researchers interested in learning more about the overall process of ML and predictive analytics, clinicians interested in gaining a better understanding of the working framework for ML so that they can better communicate with the individuals creating such models, and analytics professionals that are interested in expanding their skillset to better understand predictive modeling using healthcare data.

Here, we address some challenges specific to working with EHR data, some best practices for creating a ML model through a description of the ML process, and an overview of various different ML algorithms (with an emphasis on supervised methods but also give mention to unsupervised techniques) that can be useful for creating predictive models with healthcare data. Our goal is not to educate the reader on precisely how to utilize various different ML algorithms but to better understand the process of creating predictive models for healthcare scenarios while using ML techniques. We discuss the pros and cons of several supervised ML methods and also note some additional considerations regarding the use of ML in healthcare that are outside the scope of this manuscript. We finish with a discussion of the limitations of this paper as well as a discussion of the field of ML in healthcare research.

Challenges Specific to Healthcare Data

Common sources of healthcare data include the EHR and claims submitted to payers for healthcare services or treatments rendered. Healthcare data stem from the need to support patient care, protect clinicians from liability, and to facilitate reimbursement. Healthcare data are not documented or collected for the purpose of research; thus, unique challenges exist when
using this type of data for research. One widely used example EHR dataset is Medical Information Mart for Intensive Care III, an openly available database consisting of deidentified health data associated with about 60,000 intensive care unit admission. Different tables within the database compromise information on demographics, vital signs, laboratory test results, medications, and more [3].

It is important to understand the intent and meaning of healthcare data prior to using it as a secondary data source for research. For example, presence of a single diagnosis for coronary artery disease does not necessarily mean a patient was diagnosed with coronary artery disease; rather the diagnosis may be documented because the patient was undergoing evaluation to determine whether they had coronary artery disease and in fact coronary artery disease was ruled out. In this example, an International Disease Classification (ICD) code for coronary artery disease was documented. Such medical nomenclature, including ICD codes (for diagnoses), Current Procedural Terminology (CPT, for procedures), and RxNorm (for medications) are used to document services provided to patients but must be considered within the context of the clinical workflows where they are used. Healthcare data and medical nomenclature must be used in concert with other healthcare data to decipher the context of the clinical situation. In the case of the example above where documentation of an ICD code reflects diagnostic differential and not an actual diagnosis, there are multiple approaches that can be taken to exclude such non-diagnostic cases: including ICD codes documented on more than one encounter separated by a certain time period or including ICD codes in the absence of a CPT code for evaluation within a certain time period. The approach to defining metrics for a given characteristic/variable is complex and varies based on the specific variable. When possible, metrics used to define specific variables should align with approaches published in the literature or formalized computational phenotypes. A computational phenotype is a clinical variable such as a diagnosis that can be determined using structured data and does not require clinician interpretation or manual chart review [4]. Computational phenotypes, such as those available from eMERGE (https://emerge-network.org) or PheKB (www.phekb.org), can be used to overcome the challenges of accurately identifying certain characteristics within EHRs.

Similarly, electronic systems often include more than one field to enter a given data element. Thus, understanding which fields are useful require understanding of the clinical context or workflows. For example, there are often many fields in the EHR where blood pressure can be documented and some may represent patient-reported, which may not be relevant to all research questions. Pertinent fields need to be collapsed and labeled accordingly. In some instances, using a common data model such as the Observational Medical Outcomes Partnership (https://www.ohdsi.org/data-standardization/the-common-data-model/) can help organize healthcare data into a standardized vocabulary. A common data model is especially helpful when integrating healthcare data from disparate sources. One data field in health system A may be used differently than the same field at health system B. Common data models account for such differences, making it easier to accurately pool data from different sources.

While claims data are structured, much of healthcare data within the EHR are unstructured, documented in the form of free-text notes. It is critical to know what data are accurately represented within structured fields and what are not. Data within unstructured documentation often represent a rich source of information and may be necessary to accurately represent the situation. For example, if evaluating disease severity, patient-reported outcomes are often essential, but these are often only documented in unstructured clinical notes. When unstructured data are necessary, text mining and natural language processing (NLP) methods can be used. Such methods to transform unstructured data into structured, analyzable data are becoming more mainstream, but nonetheless do require additional time and can be highly complex.

Healthcare data are also fraught with errors and missingness. Data entry is prone to simple human error including typos and omission in both structured and unstructured data. In some instances, typos and missing data need to be addressed or corrected, but in the context of using healthcare data for ML applications, this is not always ideal. If the intent of a given ML application is to create a predictive model that will continue to use healthcare data, correction of errors would be counterintuitive, given these errors are part of the data and need to be accounted for in the model. The ML models should be created using the actual data they are being created to use, which may include representation of errors and missingness. Further, missingness should not be automatically considered an error. In healthcare, missing data can be an indication of something meaningful and worthy of evaluating. For example, absence of a given provider ordering a urine drug toxicology screen for a patient prescribed high doses of opioids may suggest suboptimal patient care and thus is important to capture. Missing data can also be because the data were irrelevant in a given situation. In healthcare, data are not always missing at random. However, another type of missing data is the product of patients receiving care across different health systems, which is unavoidable, and how it is addressed depends on the research question.

**ML Process**

The creation of a predictive model via ML algorithms is not as straightforward as some in the realm of clinical and translational research would like. However, once the process is fully understood and followed, the creation of a predictive model can be straightforward and rigorous. Fig. 1 illustrates the overall process which is described in this section. The process starts with the acquisition of a worthy dataset (of sufficient size and scope), data preparation which includes steps such as the appropriate treatment of missing data, identifying all data sources/types, and the appropriate treatment of identified errors. Next comes the selection of appropriate ML algorithms for the problem at hand as not all methods work for all types of outcomes. Once a method or methods have been chosen, the model building process can begin. After a suitable model has been built on the training dataset, the model should also be evaluated by examining how well the created model also works on the testing dataset. Finally, the ultimate model should be validated on a separate dataset before it can be used in practice for prediction. Here, we discuss the common steps necessary for creation of a predictive model based on EHR data for clinical use.

**Data Acquisition**

The data acquisition step is critically important for the success of the final predictive model. This step often involves writing the appropriate query for an EHR data warehouse to ensure that the correct data for the question at hand are obtained. Before requesting the data, a clear understanding of the research question and appropriate study designs is critical. The research question defines the scope of the data request and the data requested must
minimally address the research question. If the question is not clearly defined, it is common to omit key data elements from the request or request more data than necessary. When leveraging EHR data for research, attention must be paid to how the data are generated to minimize important biases that could undermine the study question. Selecting the appropriate study design is foundational and directs the sampling and data analysis necessary to effectively achieve the study aims or objectives. This frequently involves working with an informatician or analyst skilled in creating appropriate queries for relational databases used to store patient information. An important step is also ensuring that the database that one is working with is the most up-to-date version (or if not, knowing that is a limitation of the study).

**Data Preparation**

The EHR data acquired can be fraught with errors, whether the data are pulled directly from an EHR software system (such as Epic or Cerner) or compiled by a resident or fellow. Knowing where potential errors may lie is key in knowing how to handle the data downstream. Once potential errors have been identified, they can be properly dealt with and corrected. Data preparation also includes how one handles missing values as creating ML algorithms with vast amounts of missing data can greatly bias the resultant predictive model. Some ML methods implicitly handle missing data, but when they do not, several methods exist for handling missingness. One measure is to remove subjects who have any missing data. This will reduce the sample size of the dataset to ensure only complete information is analyzed, but this approach often introduces selection biases. Another option is to impute the missing data in some fashion. Common imputation methods are replacing the missing value with the mean or median for a given variable, replacing the missing value with zero or the most commonly occurring value for a given variable, or more intensive computational methods such as k-nearest neighbor imputation or methods involving regression. Which method is best to choose depends on the structure of the data and why the value is missing [5]. In addition to cleaning the data, the data preparation step also includes variable selection/feature reduction. While most algorithms will create a model from any number of variables, culling the number of variables chosen for the initial model creation can help ensure the model is not overly complicated or large. Common methods for variable selection include random forests (choose the top x number of variables from the variable importance list), least absolute shrinkage and selection operator [6], principal component analysis [7] (choose the top x number of principal components), stepwise selection procedures, and basic hypothesis testing (choose those variables with a p-value less than a prespecified threshold). Common feature selection methods include filter methods and wrapper methods. Filter methods are where one utilizes some method (a hypothesis test or correlation coefficient for example or linear discriminant analysis) to filter the variables based upon some prespecified value or cutoff [8–10]. Wrapper methods are an iterative process where variables are selected, assessed for model accuracy, and then revised based on performance. Common wrapper methods include forward selection, backward elimination, and recursive feature elimination. The exact number of variables to select is subjective and should be based on the total sample size within the dataset. Additionally, one should also consider model utility in making the decision for how many variables to include in the final model. For instance, if a model is to be clinically relevant and utilized in practice, a physician commonly prefers a model with fewer variables instead of one with 20 as that means less underlying data/testing is needed to inform potential decision-making. These feature reduction and screening methods can be used with or without an outcome in supervised and unsupervised methods, respectively; however, feature screening methods that look at the association between predictors and an outcome must be based on the training data only in order to prevent overfitting/bias [11].

**Choosing a Method**

Once your dataset has been checked for errors and missing values have been dealt with, it is time to choose a method for the creation of a predictive model. Not all methods work best for all questions of interest, so it is important to know the format of the outcome variable (is it binary, categorical, continuous?) as well as the format/structure of the independent variables (are they categorical, continuous, normally distributed, correlated, longitudinal?). It is also important to understand if you will be able to use a supervised method or an unsupervised method. Supervised methods assume that the ultimate outcome is known (for instance, this person has Stage 1 cancer vs Stage 2 cancer). Unsupervised methods do not have such assumptions.

**Training/Testing**

Despite which method is chosen above, the process of creating a model is similar. Some users are tempted to throw all the data into an algorithm and examine the result. This is less than ideal for creating predictive models that can be useful in the clinic. The reason being is that such a model may be overfit for the data at hand (i.e. the model works really well on the data that were used to create it, but it does not perform well in other scenarios). To avoid overfitting, the model should be created initially on training data and then separately evaluated on testing data. Typically with developing and
validating models (training and testing), the dataset is randomly split into a training set (80% of the data) and a testing set (the remaining 20% of the data). While the 80/20 split is commonly used, other splits can be used as well. What is important is that the training set is large enough in sample size to yield meaningful results and also has characteristics that resemble the entire dataset [12]. The model is initially created using only the training set. Evaluation metrics are examined, and then the same model is run using the testing dataset, and evaluation metrics for it are examined. Sometimes, cross-validation techniques are also used on the training dataset.

In general, cross-validation is any approach that leaves some of the data out when creating the initial model and then includes it in a testing fashion [11, 13–17]. This includes splits other than 80/20 (e.g. 60/40), repeated cross-validation (e.g. 80/20 split repeated five times where each set is held out once), bootstrap sampling [18–21], or subsampling. No matter the splitting method, if using a repeated cross-validation technique, the process is repeated multiple times so that different subsets of data are left out for separate runs of the model building process, and the model performance metrics are averaged for each subset of testing data to produce an overall average performance metric [22–26].

The amount of data and overall sample size required for prediction models depends on multiple factors. The sample size considerations are essential in the design phase of prediction modeling techniques as the sample size is dependent on a variety of factors, including the number of outcome events, the prevalence of the outcome or the fraction of positive samples in the total sample size, and the number of candidate predictor variables considered. Additional considerations include the number of classes the model is to predict. If the validation plan for the model is to develop the model on a subset of data and then test the model on the remaining subset, the sample size considerations should account for the split dataset, particularly if the prevalence of the event is low, to ensure the testing set will have ample events to perform.

**Training Set Sample Size Planning for Predictive Modeling**

Healthcare databases may contain thousands to hundreds of thousands of available subjects. Given such a large sample size, it may not be necessary to formally estimate the sample size needed for building a prediction model. In other cases, the number of available subjects will be limited and a formal sample size calculation will be more useful. As discussed in Figureoa [27], there are two main approaches to estimate the training dataset sample size needed for building a prediction model: “learning curve” and “model-based” approaches. “Learning curve” methods require preliminary data on a set of subjects with all features/predictors and outcome of interest measured [27–29]. One chooses a specific type of prediction model and estimates the prediction accuracy of the model when varying the sample size by leaving some of the subjects out in an iterative manner. A “learning curve” is then fit to the resulting prediction accuracies compared to the sample size used to fit the model. One can then extrapolate from the learning curve to estimate the sample size needed to obtain a desired level of prediction accuracy. The main downside of this approach is the requirement of substantial preliminary data. In contrast, “model-based” approaches do not require preliminary data but make strong assumptions about the type of data used in the study (e.g. all predictors are normally distributed) [30–32]. Dobbin et al. offer an online calculator for estimating the necessary sample size in the training dataset that only requires three user input parameters [31,33]. Despite its strong assumptions, Dobbin et al. argue that their method is “conservative” in that it tends to recommend sample sizes that are larger than necessary. McKeigue provide R code for their method which also only requires three user input parameters [32].

**Model Evaluation**

Once a model has been created using the training dataset, the model should be evaluated on the test dataset to assess how well it predicts outcomes for new subjects that were not used to build/train the model. The reason for doing this is to ensure that the model is not overfit for the data it was trained on and to also ensure that the model is not biased toward particular values within the training dataset [11]. Random chance alone could have impacted the model fit from the training data, and evaluating the model fit on the testing data can diminish this impact [34,35]. Several methods exist for evaluating predictive accuracy, and usually a combination of techniques are used. Evaluation methods for supervised learning with categorical outcomes include assessing discrimination through the area under the receiver operating characteristic curve, which can be obtained by calculating the C-statistic (“Concordance” statistic) and partial C-statistic for the various models [36]. Additional steps include evaluating a confusion matrix which indicates how many individuals the model correctly classifies and how many individuals are incorrectly classified. See Table 1 for a list of prediction accuracy metrics that can be used for particular types of outcomes (e.g. continuous, binary, multi-category, or time-to-event). The chosen evaluation metric would be calculated for the training data and then separately for the testing data. Ideally, the prediction accuracy would be high for both the training and testing datasets. Calibration methods can be used to assess how well the predicted outcomes correlate with the true outcomes, including using scatter plots, reporting a regression slope from a linear predictor, or using the Hosmer–Lemeshow test to compare accurate predictions by decile of predicted probability [37,38]. High accuracy for the training data with low accuracy for the testing data indicate that the model is overfit for the data and will likely not generalize well to other settings. Lastly, special methods should be used when evaluating predictive performance for categorical outcomes with unbalanced classes (i.e. when the number of subjects per class is not approximately equal), such as over-/undersampling, cost-sensitive methods, or precision and recall curves [39,40].

| Outcome type                  | Prediction accuracy metric<sup>a</sup>                                                                 |
|-------------------------------|-------------------------------------------------------------------------------------------------------------|
| Continuous                    | mean squared error (MSE), root mean squared error (RMSE), mean absolute error (MAE), proportion of outcome variance explained (R²) |
| Binary                        | AUC, C-statistic, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), precision, recall |
| Categorical with three or more categories | "one-versus-all"<sup>b</sup> versions of metrics for binary outcome, multinomial log-likelihood |
| Time-to-event                 | C-statistic, Integrated Brier Score                                                                        |

<sup>a</sup>Most of the above performance metrics are defined in Kuhn [79]. For machine learning with time-to-event outcomes, Ishwaran [111] used the C-statistic [36], while Bou-Hamad [112] used the Integrated Brier Score [113].

<sup>b</sup>For a categorical outcome with three or more categories, “one-versus-all” versions of metrics for a binary outcome can be used which assess prediction accuracy for one category versus all other categories combined.
Parameter Tuning
If the model created does not fit the data well, or if the model is overfit for the training data, parameter tuning is typically the next step in the final predictive model creation process. Parameter tuning involves fine-tuning of parameters that control the overall complexity of the ML model. Hyperparameter tuning is sometimes needed when using various techniques (such as neural networks, support vector machines, or k-nearest neighbors) to optimize the parameters that help define the model architecture. Hyperparameters are parameters that cannot be automatically learned from the model building process, and rather, the user needs to try a grid of values and use cross-validation or some other method to find the optimized value [41]. Olson et al. and Lou provide guidance on several different methods for the tuning of hyperparameters and evaluate different methods for different algorithms [42,43]. Tuning of the hyperparameters should only be done utilizing the training data. The model creation process is highly iterative, so once a change is made, the whole process is re-run and re-evaluated.

Validation
Finally, once a model has been selected as being optimal for both the training and testing datasets, and the variables of interest are selected, the model ultimately needs to be tested a final time on an independent dataset, known as the validation dataset, before it can realistically be used in a clinical setting. This is to ensure the model actually works well in practice, and on a dataset that was independently collected (frequently from a different clinical setting, but with the same initial standards as the training dataset).

How ML is Used in Clinical and Translational Research
The use of ML with healthcare data can help with several different types of clinical and translational research goals [44–46]. The type of aim or research question will determine which methods are ideal to use and which types of biases and misconceptions will be applicable and should be avoided. The use of ML with healthcare data can be generally classified into four different goals: (1) diagnostics and clinical decision support tools, (2) -ome wide association studies, (3) text mining, and (4) causal inference [47].

Diagnostics and clinical decision support tools are designed to give healthcare workers and patients specific information to enhance their clinical care. These tools are often specialized to appropriately filter applicable data based on an individual patient’s condition at a certain time. For example, a clinical decision support tool might utilize the longitudinal health history of a patient with high blood pressure to estimate their risk for a myocardial infarction in the near future. Techniques used for accomplishing this that have been implemented with ML methods include imaging diagnostics, risk stratification, and identification of prognostic subgroups.

-ome-wide” association studies leverage measurements of large numbers of different variants in an -ome system to see if any of them are associated with a disease outcome or health characteristic. These could include the genome, phenome, exposome, microbiome, metabolome, proteome, or transcriptome; often referred to generally as ‘omics data. For example, a genome-wide association study might identify a small list of polymorphisms that are associated with an increased risk for obesity. These types of methods are also used to predict clinical outcomes, like the effectiveness of a drug, or for the identification of gene–gene and gene–environment interactions. See Libbrecht and Noble [48], Ghosh et al. [49], and Zhou and Gaillons [50] for a review of ML methods applied in specific types of ‘omics data, or for integrating multiple ‘omics data sources [51,52].

Text mining works by automating data extraction from unstructured clinical notes. The applications can include the identification of patients that might benefit from participation in clinical trials, the removal of protected health information from clinical records to be used for research, the conduct of a systematic literature review, and automated infectious disease surveillance systems [53].

Causal inference is the process of making an inference about a specific intervention or exposure with respect to its effect. For example, a causal inference study could be conducted with the goal of determining if taking a specific drug increases the expected life-span of patients with a certain disease. It is important to consider confounding pathways, or those characteristics that could vary with both the intervention/exposure and the disease outcome, so that we are not misinterpreting an association as a causal effect. Techniques used for accomplishing this that have been implemented with ML methods include propensity score weighting [54], targeted maximum likelihood estimation, marginal structural models, heterogeneous treatment effects, and causal structure learning [55–58].

Overview of ML Methods
Artificial intelligence (AI) is a scientific field within computer science that focuses on the study of computer systems that perform tasks and solve problems that historically required human intelligence. ML is a subfield of AI that focuses on a special class of algorithms that can learn from data without being explicitly programmed. This is accomplished by making inferences based on patterns found in data. Although some human specification is required, ML algorithms overall require less human input than more traditional statistical modeling (i.e. deciding which variables to include a priori). In general, there are three main ways that a machine might learn from data: (1) supervised ML, (2) unsupervised ML, and (3) reinforcement learning.

Supervised ML, most often used for prediction modeling, works by mapping inputs to labeled outputs. This is used only when each input used to train the model has a labeled output, for example, an input of longitudinal measurements on a person collected during their hospitalization might be used with a labeled output of in-hospital mortality or unplanned readmission within 30 days of discharge [59]. Supervised ML is also referred to more generally as “predictive modeling,” or “regression” for quantitative outcomes, and “classification” for categorical outcomes. Often, data with labels are used to train a supervised ML algorithm and then the algorithm is used to predict unknown labels for a set of new inputs. Mathematical techniques used to develop supervised ML models include decision trees and random forests [60–62], gradient boosting [63–65], neural networks and deep learning [66–71], support vector machines [72], and regularized/penalized regression [73].

Unsupervised ML works by finding patterns in unlabeled input data. This category is commonly used for segmentation and clustering problems such as identifying disease sub-phenotypes or pattern recognition. For example, a registry of patients diagnosed with asthma might be classified into different subgroups based on their sensitivity to different types of indoor and outdoor allergens, lung function, and presence of wheezing [74]. Mathematical techniques used to develop unsupervised ML models include clustering (hierarchical, k-means), dimensionality reduction, Gaussian
mixture models, principal component analysis, and independent component analysis.

**Reinforcement learning** works by improving a sequence of decisions to optimize a long-term outcome through trial and error [75]. It is similar to supervised learning, but a reward mechanism is used in place of a labeled output. This category is often used within healthcare to evaluate and improve policies. For example, a longitudinal series of decisions regarding treatment options must be made by a clinician within the context of managing sepsis (e.g. mechanical ventilation, sedation, vasopressors) [76]. Unlike supervised learning which makes a one-time prediction, the output of a reinforcement learning system can affect both the patient’s future health as well as future treatment options. Often times, a reinforcement learning algorithm will make a short-term decision based on what it believes will result in the best long-term effect, even if that means a suboptimal short-term outcome. Mathematical techniques used to develop reinforcement learning models include neural networks, temporal difference algorithms, Q-learning, and state-action-reward-state-action.

**Pros/Cons of Supervised ML Methods**

Fernández-Delgado et al. [77] compared the predictive accuracy of 179 ML models (sorted into 17 “families” of different model types) across 121 real datasets and found that random forests were consistently among the best predictive models. Thus, random forests can be recommended as one of the best “off-the-shelf” ML models. Nevertheless, one can never know a priori which model will produce the highest predictive accuracy for a given application, thus it is common practice to fit several different ML models and use cross-validation to select a final model that has the highest predictive accuracy. Each ML model has its own pros and cons which should be taken into consideration when deciding which model to use. In addition, when comparing multiple ML models, it is frequently useful to also compare with one or more simple, traditional statistical models such as linear or logistic regression (or penalized versions thereof). For example, a systematic review of 71 clinical predictive modeling papers found no evidence for a difference in predictive accuracy when comparing logistic regression (or penalized regression) with a variety of ML models [78].

Table 2 compares several key properties of different ML models and classical statistical models such as linear or logistic regression. These properties will now be briefly summarized and can be used to help decide which ML model to use for a given problem. For a comprehensive introduction to these ML models, see [79–81].

In contrast to classical statistical models like linear or logistic regression, all of the ML models considered allow the number of predictors (“P”) to be larger than the number of subjects (“N”), that is, “P > N.” In addition, most of the ML models considered automatically allow for complex nonlinear and interaction effects, whereas classical methods (and penalized regression) generally assume linear effects with no interactions. One can manually explore a small number of nonlinear or interaction effects in classical models, but this becomes practically infeasible with more than a handful of predictors, in which case, ML models that automatically allow for complex effects may be more appropriate.

Several ML methods can handle a large number of irrelevant predictors (i.e. predictors that have no relationship with the outcome) without needing to first identify and remove these predictors before fitting the model. Tree-based methods [61] (e.g.
classification and regression tree (CART) [82], random forests, boosted trees) use a sequential process that searches through all predictors to find the “optimal” predictor (that best improves the predictive accuracy) to add to the tree at each step in the tree-building process. Multivariate adaptive regression splines (MARS) [83] uses a similar “step-wise” or sequential model building approach. In doing so, these methods automatically search for the most important predictors to include at each step of the model-fitting process, thereby disregarding unimportant predictors. Penalized regression shrinks regression coefficients toward zero, effectively disregarding unimportant predictors.

ML models typically contain one or more main “tuning parameters” that control the complexity of the model. As described in the section on Training/Testing, one can use cross-validation or the bootstrap to select optimal values for these tuning parameters. In general, the more tuning parameters a model has, the more challenging it is to fit the model, since one needs to find optimal values for all tuning parameters which requires searching across a large grid of possible values. Models like CART, random forests, MARS, and penalized regression, often only have fewer tuning parameters that need to be optimized and thus may be considerably easier to implement in practice. In contrast, boosted trees, support vector machines, and neural networks contain more tuning parameters and thus can be more computationally challenging to optimize.

Unlike most ML models, tree-based methods (e.g. CART, random forests, boosted trees) have several additional unique benefits: they are robust to noise/outliers in the predictors [11,79], and can naturally handle missing values in the predictors using a technique called “surrogate splits” [61]. Although the usual adage of “garbage-in garbage-out” still applies, tree-based methods require minimal data pre-processing of the predictors. For example, most models require standardizing all predictors to be on the same scale, whereas trees can naturally handle a mix of categorical and continuous predictors measured on their original scales, which may be beneficial for EHR data. However, it is worth noting that earlier versions of trees are biased toward favoring categorical variables with more categories and correlated predictors. “Conditional inference trees,” a newer framework for fitting tree-based models, have solved these problems [61,84–86]. Among the models considered in Table 2, neural networks, support vector machines, and boosted trees generally have the longest computation time, followed by random forests. Although rapid advances in computing power and parallel computing means that all of these methods will still be computationally feasible for most applications.

When deciding what ML model to use, it is also important to consider the format/type of outcome that you are trying to predict. Although not listed, all of the models in Table 2 have been extended to handle continuous, binary, or multi-category outcomes. However, ML methods are still underdeveloped for handling longitudinal or censored time-to-event (“survival”) outcomes. Some recent work has extended tree-based methods (e.g. CART, random forests) to handle such outcomes [87–89].

Lastly, the models can be compared by how “interpretable” they are. Classical statistical models, CART (“single tree”), MARS, and penalized regression are all easier to interpret. More complex ML models like random forests, boosted trees, support vector machines, and neural networks are much harder to interpret. In general, one can fit a variety of ML models and assess their predictive accuracy using cross-validation. If the cross-validated predictive accuracy of a more interpretable model is comparable to an uninterpretable model, then the more interpretable model should be preferred. The next section discusses tools that can be used to help interpret any ML model.

Interpreting Black-Box ML Models

ML models are often criticized as being “black-box” models: data are input into a mysterious “black box” which then outputs predictions. However, the user often lacks an explanation or understanding for why the mysterious black box makes a given prediction. Making black-box ML models more interpretable is an ongoing area of research, and we will briefly summarize several important contributions, all of which are implemented in the iml (“interpretable machine learning”) R package [90].

Many ML models produce a type of “variable importance” score [79] for each predictor in the model, allowing the user to rank the predictors from most to least important in their ability to predict the outcome. In addition, one can use “partial dependency plots” [11] (PDPs) to visualize the estimated relationship between the outcome and a specific predictor in the model. For each possible value of the predictor of interest, the PDP will show you the expected value of the outcome, after adjusting for the average effects of all other predictors. For example, one may first rank predictors from most to least important based on their variable importance scores and then use PDPs to visualize the relationship between the outcome and each of the top 5 or 10 most important predictors. Lastly, Friedman’s H-statistic [91] can be used to identify predictors involved in interactions.

Recently, several methods have been developed to help understand why a ML makes a prediction for a particular subject. LIME [92] (“Local Interpretable model explanations”) uses simpler more interpretable models (e.g. linear or logistic regression) to explain how a given subject’s feature values affects their prediction, and the user can control exactly how many features are used to create the “explanation.” The basic idea of LIME is to weigh all subjects by how similar they are to the subject of interest and then fit a simpler interpretable model “locally” by applying these weights. This simpler model is then used to provide an explanation for why the ML model made the prediction for the given subject (or subjects who have features similar to that subject). “Shapley values” [93], originally developed in game theory, are another method for explaining predictions from ML models. Shapley values explain how a subject’s feature values (e.g. gender, age, race, genetics) affect the model’s prediction for that subject compared to the average prediction for all subjects. For example, suppose the model’s average predicted probability of having a particular disease is 0.10. Suppose for a particular subject of interest, “Sam,” the probability of having the disease is 0.60, that is, 0.50 higher than the average prediction. To explain Sam’s prediction, each feature included in the model will get a “Shapley value” that explains how the values of Sam’s features affected the prediction. For example, Sam’s gender increased the prediction by 0.15, Sam’s age increased the prediction by 0.30, and Sam’s race increased the prediction by 0.05. Notice the sum of the Shapley values equals 0.50, which was the difference between Sam’s prediction and the average prediction for all subjects. See Molnar [94] for more information on methods for interpreting ML models.

Open-Source Software for ML

All of the ML models discussed can be fit within the free open-source software R [95]. The caret R package [96] and tidymodels R package [97] both provide a unified framework for training/tuning and testing over 200 ML models. Table 2 lists a few example...
R packages for fitting specific ML models. See the “CRAN Task View Machine Learning & Statistical Learning” website [98] for a more comprehensive list of ML R packages. Python also offers free open-source software for ML [99,100].

Special Considerations of ML in Healthcare Research

Interpretation

As previously discussed, the “black box” nature of ML methods makes it difficult to understand and interpret the predictions. Although there are some tools that can be used to help interpret ML, further research is still needed for making ML more transparent and explainable. Transparency is especially important when used to make decisions that will impact a patient’s health.

Fairness/Equity

ML learns from data recorded on past historical examples. However, such historical data can also capture patterns of preexisting healthcare disparities and biases in treatment and diagnosis. ML models trained using such data may further perpetuate these inequities and biases [101]. In addition, if a particular subgroup of patients is under-represented or more likely to have missing data used to train the ML model, then the ML model may produce inaccurate predictions for the subgroup, which can also further exacerbate existing healthcare disparities [102]. Methods and guidelines are being developed to help ensure fairness and equity when using ML models [101–103], but more work is needed. After clinical implementation, ML models should be regularly evaluated for fairness and equity among different minority subgroups. There exist several definitions of fairness and equity within precision medicine that cannot all be simultaneously satisfied, but in general, model evaluation should be conducted for different minority subgroups to ensure that the model performs equally well within each group.

Need for Translational Prospective Studies Demonstrating Utility of ML

The vast majority of ML in healthcare has been demonstrated using retrospective historical data where outcomes are already known [44–46]. There is a crucial need to demonstrate the utility of ML-based prediction and decision/support tools in real-time prospective studies.

Legal/Regulatory Issues

If an incorrect medical decision is made based on a complex ML decision support tool, it is unclear what entity should be held liable for that decision [45]. Government regulations for ML-based clinical support tools are still being developed [104].

Limitations

The authors realize that we have not included mention of several new and important techniques namely in the fields of deep learning, AI, and NLP. We agree that the methods mentioned above are important in the field of predictive modeling and have a place in the analysis of healthcare data. We have chosen to exclude them from this paper as their use is more advanced and requires a more in-depth knowledge of the underlying mathematical and conceptual processes needed to utilize such applications. Deep learning, for instance, involves utilizing multiple layers of neural networks where each network trains a more complicated task. TensorFlow is one example of deep learning and Pytorch is another. Reinforcement learning trains a system to answer multiple questions in sequence. NLP allows data to be extracted from physicians’ notes to be used in analytical applications. All of these are important, recent advances in the field of predictive analytics. Their use, however, is more complex (more training steps, the creation of multiple networks) than the more routine ML process presented above and thus outside the scope of this paper [105,106]. Additionally, the use of AI and NLP in healthcare is still under scrutiny [107,108] and best practices for their use are still being adopted.

Discussion

ML algorithms have the potential to be powerful and important tools for healthcare research. Here, we have provided researchers with cautionary notes regarding the use of EHR data, insurance databases, and other clinical data with ML algorithms. We have presented the healthcare researcher with a ML pipeline for preparing the data, running the data through various algorithms using separate training/testing datasets, evaluating the created predictive model, tuning any necessary model parameters, and finally validating the predictive model on a separate dataset. In addition, we mention several commonly used ML algorithms frequently referenced in the healthcare literature, and the pros/cons of various supervised methods. Finally, we also mention several considerations for using ML algorithms with healthcare data that, while important, are beyond the scope of this article. Our goal with the concepts and methods described in this article is to educate the healthcare researcher to better understand how to properly conduct a ML project for clinical predictive analytics. We should also note that ML methods do not always perform better than traditional statistical-based methods such as logistic regression [109]. The clinician or translational researcher should familiarize themselves with the differences between traditional statistical-based methods and ML methods and utilize what works best for their specific questions of interest [110].

Acknowledgments. This study was supported by the following grants from the National Institutes of Health: UL1TR001439 (H.M.S.), UL1TR001425 (C.B., J. M-D), UL1 TR002535 (J.A., K.E.T.). Contents are the authors’ sole responsibility and do not necessarily represent official NIH views.

Disclosures. No authors reported conflicts of interest.

References

1. Blumenthal D, Tavenner M. The “meaningful use” regulation for electronic health records. The New England Journal of Medicine 2010; 363: 1–3.
2. Liu Y, et al. How to read articles that use machine learning: users’ guides to the medical literature. JAMA 2019; 322(18): 1806–1816.
3. Johnson AE, et al. MIMIC-III, a freely accessible critical care database. Scientific Data 2016; 3: 160035.
4. Richesson R, Smerek M. Electronic health records-based phenotyping. Rethinking Clinical Trials: A Living Textbook of Pragmatic Clinical Trials, 2016; 2014.
5. Kang H. The prevention and handling of the missing data. Korean Journal of Anesthesiology 2013; 64(5): 402–406.
6. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society: Series B (Methodological) 1996; 58(1): 267–288.
7. Abdi H, Williams JI. Principal component analysis. Wiley Interdisciplinary Reviews: Computational Statistics 2010; 2(4): 433–459.
8. Liu H, Motoda H. Feature Selection for Knowledge Discovery and Data Mining (The Springer International Series in Engineering and Computer Science). Norwell, MA: Kluwer Academic, 1998.

9. Liu H, Motoda H. Computational Methods of Feature Selection (Chapman & Hall/CRC Data Mining and Knowledge Discovery Series). 1st ed. Boca Raton, FL: Chapman & Hall/CRC, 2007.

10. Wang L, Wang Y, Chang Q. Feature selection methods for big data bioinformatics: a survey from the search perspective. Methods 2016; 111: 21–31.

11. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. Berlin: Springer Science & Business Media, 2009. 245–247.

12. https://developers.google.com/machine-learning/crash-course/training-and-test-sets/splitting-data.

13. Stone M. Cross-validatory choice and assessment of statistical predictions. Journal of the Royal Statistical Society Series B 1974; 83: 111–147.

14. Stone M. An asymptotic equivalence of choice of model by cross-validation and Akaïke’s criterion. Journal of the Royal Statistical Society Series B 1977; 39: 44–47.

15. Allen D. The relationship between variable selection and data augmentation and a method of prediction. Technometrics 1974; 16: 125–127.

16. Golub G, Heath M, Wahba G. Generalized cross-validation as a method for choosing a good ridge parameter. Technometrics 1983; 21: 215–224.

17. Wahba G. Spline bases, regularization, and generalized cross-validation for solving approximation problems with large quantities of noisy data. In: Proceedings of the International Conference on Approximation Theory in Honour of George Lorentz. Austin, TX: Academic Press, 1980. 905–912.

18. Efron B, Tibshirani R. An Introduction to the Bootstrap. London: Chapman and Hall; 1993.

19. Efron B. Bootstrap methods: another look at the jackknife. Annals of Statistics 1979; 7: 1–26.

20. Efron B. Estimating the error rate of a prediction rule: some improvements on cross-validation. Journal of the American Statistical Association 1983; 78: 316–331.

21. Efron B. How biased is the apparent error rate of a prediction rule? Journal of the American Statistical Association 1986; 81: 461–470.

22. Breiman L, Spector P. Submodel selection and evaluation in regression: the X-random case. International Statistical Review 1992; 60: 291–319.

23. Breiman L. The little bootstrap and other methods for dimensionality reduction in regression: X-fixed prediction error. Journal of the American Statistical Association 1992; 87: 738–754.

24. Shao J. Bootstrap model selection. Journal of the American Statistical Association 1996; 91: 655–660.

25. Zhang P. Model selection via multifold cross-validation. Annals of Statistics 1993; 21: 299–311.

26. Kohavi R. A study of cross-validation and bootstrap accuracy estimation and model selection. In: International Joint Conference on Artificial Intelligence (IJCAI), Burlington, MA: Morgan Kaufmann; 1995. 1137–1143.

27. Figueroa RL, et al. Predicting sample size required for classification performance. BMC Medical Informatics and Decision Making 2012; 12(1): 8.

28. Mukherjee S, et al. Estimating dataset size requirements for classifying DNA microarray data. Journal of Computational Biology 2003; 10(2): 119–142.

29. Dobbin KK, Song X. Sample size requirements for training high-dimensional risk predictors. Biostatistics 2013; 14(4): 659–662.

30. Dobbin KK, Simon RM. Sample size planning for developing classifiers using high-dimensional DNA microarray data. Biostatistics 2007; 8(1): 101–117.

31. Dobkin KK, Zhao Y, Simon RM. How large a training set is needed to develop a classifier for microarray data? Clinical Cancer Research 2008; 14(1): 108–114.

32. McKeigue P. Sample size requirements for learning to classify with high-dimensional biomarker panels. Statistical Methods in Medical Research 2019; 28(3): 904–910.

33. National Cancer Institute, Division of Cancer Treatment & Diagnosis. Sample size planning for developing classifiers using high dimensional data [Internet]. 2016. (https://linus.nci.nih.gov/hrb/samplesize/samplesize4GE.html)

34. James G, et al. An Introduction to Statistical Learning with Applications in R. New York: Springer, 2013.

35. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in Medicine 1996; 15(4): 361–387.

36. Harrell FE, et al. Evaluating the yield of medical tests. JAMA 1982; 247(18): 2543–2546.

37. Steyerberg EW, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010; 21(1): 128–138.

38. Van Calster B, et al. A calibration hierarchy for risk models was defined: from utopia to empirical data. Journal of Clinical Epidemiology 2016; 74: 167–176.

39. He H, Garcia EA. Learning from imbalanced data. IEEE Transactions on Knowledge and Data Engineering 2009; 21(9): 1263–1284.

40. Saito T, Rehmsmeier M. The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced data-sets. PloS One 2015; 10(3). https://doi.org/10.1371/journal.pone.0118432

41. Preuveneers D, Tsingopoulos I, Joossen W. Resource usage and performance trade-offs for machine learning models in smart environments. Sensors (Basel). 2020; 20(4): 1176.

42. Olson RS, et al. Data-driven advice for applying machine learning to bioinformatics problems. Pacific Symposium on Biocomputing 2018; 23: 192–203.

43. Luo G. A review of automatic selection methods for machine learning algorithms and hyper-parameter values. Network Modeling Analysis in Health Informatics and Bioinformatics 2016; 5: 18.

44. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine 2019; 25(1): 44–56.

45. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nature Biomedical Engineering 2018; 2(10): 719–731.

46. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. New England Journal of Medicine. 2019; 380(14): 1347–1358.

47. Bi Q, et al. What is machine learning? A primer for the epidemiologist. American Journal of Epidemiology. 2019; 188(12):2222–2239.

48. Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. Nature Reviews Genetics 2015; 16(6): 321–332.

49. Ghosh T, et al. ”Predictive Modeling for Metabolomics Data.” Computational Methods and Data Analysis for Metabolomics. New York: Humana, 2020. 313–336.

50. Zhou YH, Paul GP. A review and tutorial of machine learning methods for microbiome host trait prediction. Frontiers in Genetics 2019; 10: 579.

51. Li Y, Wu FX, Ngom A. A review on machine learning principles for multi-view biological data integration. Briefings in Bioinformatics 2018; 19(2): 325–340.

52. Huang S, Chaudhary K, Garmire LX. More is better: recent progress in multi-omics data integration methods. Frontiers in Genetics 2017; 8: 84.

53. Khan A, et al. A review of machine learning algorithms for text-documents classification. Journal of Advances in Information Technology 2010; 1(1): 4–20.

54. Lee BK, Lessler J, Stuart EA. Improving propensity score weighting using machine learning. Statistics in Medicine 2010; 29(3): 337–346.

55. Athey S, Guido W. Imbens: machine learning methods that economists should know about. Annual Review of Economics 2019; 11(1), 685–725.

56. Van der Laan MJ, Rose S. Targeted Learning in Data Science. Berlin: Springer International Publishing, 2018.

57. Wendling T, et al. Comparing methods for estimation of heterogeneous treatment effects using observational data from health care databases. Statistics in Medicine 2018; 37(23): 3309–3324.

58. Athey S, Tibshirani J, Wager S. Generalized random forests. Annals of Statistics 2019; 47(2): 1148–1178.

59. Rajkomar A, et al. Scalable and accurate deep learning with electronic health records. NPJ Digital Medicine 2018; 1: 18.

60. Breiman L. Random forests. Machine Learning 2001; 45(1): 5–32.

61. Strobl C, Malley J, Tutz G. An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests. Psychological Methods 2009; 14(4): 323.

62. Boulesteix AL, et al. Overview of random forest methodology and practical guidance with emphasis on computational biology and bioinformatics. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery 2012; 2(6): 493–507.
63. Friedman JH. Stochastic gradient boosting. *Computational Statistics & Data Analysis* 2002; 38(4): 367–378.
64. Natekin A, Knoll A. Gradient boosting machines, a tutorial. *Frontiers in Neuro robotics* 2013; 7: 21.
65. Chen T, Guestrin C. Xgboost: A scalable tree boosting system. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, 2016.
66. LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature* 2015; 521(7553): 436–444.
67. Schmidhuber J. Deep learning in neural networks: an overview. *Neural Networks* 2015; 61: 85–117.
68. Miotto R, et al. Deep learning for healthcare: review, opportunities and challenges. *Briefings in Bioinformatics* 2018; 19(6): 1236–1246.
69. Angermueller C, et al. Deep learning for computational biology. *Molecular Systems Biology* 2016; 12(7): 878.
70. Ravi D, et al. Deep learning for health informatics. *IEEE Journal of Biomedical and Health Informatics* 2016; 21(1): 4–21.
71. Litjens G, et al. A survey on deep learning in medical image analysis. *Medical Image Analysis* 2017; 42: 60–88.
72. Cristianini N, Shawe-Taylor J. An Introduction to Support Vector Machines and other Kernel-Based Learning Methods. Cambridge: Cambridge University Press, 2000.
73. Hastie T, Tibshirani R, Wainwright M. *Statistical Learning with Sparsity: The Lasso and Generalizations*. Boca Raton, FL: CRC Press, 2015.
74. Haldar P, et al. Cluster analysis and clinical asthma phenotypes. *American Journal of Respiratory and Critical Care Medicine* 2008; 178(3):218–224.
75. Kaelbling LP, Littman ML, Moore AW. Reinforcement learning: a survey. *Journal of Artificial Intelligence Research* 1996; 4:237–285.
76. Gottesman O, et al. Guidelines for reinforcement learning in healthcare. *Nature Medicine* 2019; 25(1):16–18.
77. Fernández-Delgado M, et al. Do we need hundreds of classifiers to solve real world classification problems? *The Journal of Machine Learning Research* 2014; 15: 3133–3181.
78. Jie MA, et al. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. *Journal of Clinical Epidemiology* 2019; 110: 12–22.
79. Kuhn M, Johnson K. *Applied Predictive Modeling*. Berlin: Springer, 2013.
80. Spratt HM, Ju H. Statistical approaches to candidate biomarker panel selection. *Advances in Experimental Medicine and Biology* 2016; 919: 463–492.
81. Spratt H, Ju H, Brasier AR. A structured approach to predictive modeling of a two-class problem using multidimensional data sets. *Methods* 2013; 61(1): 73–85.
82. Loh WY. Classification and regression trees. *Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery* 2011; 1(1): 14–23.
83. Friedman JH. Multivariate adaptive regression splines. *The Annals of Statistics* 1991; 19(1): 1–67.
84. Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: a conditional inference framework. *Journal of Computational and Graphical Statistics* 2006; 15(3): 651–674.
85. Strobl C, et al. Bias in random forest variable importance measures: illustrations, sources and a solution. *BMC Bioinformatics* 2007; 8(1): 25.
86. Strobl C, et al. Conditional variable importance for random forests. *BMC Bioinformatics* 2008; 9(1): 367.
87. Sela B, Simonoff JS. RE-EM trees: a data mining approach for longitudinal and clustered data. *Machine Learning* 2012; 86: 169–207.
88. Bou-Hamad I, Laroque D, Ben-Ameur H. A review of survival trees. *Statistics Surveys* 2011; 5: 44–71.
89. Speiser JL, et al. BiMM forest: a random forest method for modeling clustered and longitudinal binary outcomes. *Chemometrics and Intelligent Laboratory Systems* 2019; 185: 122–134.
90. Molnar C, Casalicchio G, Bischl B. iml: an R package for interpretable machine learning. *Journal of Open Source Software* 2018; 3: 786.
91. Friedman JH, Popescu BE. Predictive learning via rule ensembles. *The Annals of Applied Statistics* 2008; 2: 916–954.
92. Ribeiro MT, Singh S, Guestrin C. Why should I trust you? Explaining the predictions of any classifier. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. New York: Association for Computing Machinery, 2016, pp. 1135–1144.
93. Strumbelj E, Kononenko I. Explaining prediction models and individual predictions with feature contributions. *Knowledge and Information Systems* 2014; 41: 647–665.
94. Molnar C. *Interpretable machine learning: a guide for making black box models explainable* [Internet]. 2019. (https://christophm.github.io/interpretable-ml-book)
95. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna: R Foundation for Statistical Computing. (https://www.R-project.org/), 2018.
96. Kuhn M. Building predictive models in R using the caret package. *Journal of Statistical Software* 2008; 28(5): 1–26.
97. https://cran.r-project.org/web/packages/tidymodels/index.html.
98. https://cran.r-project.org/web/views/MachineLearning.html.
99. Raschka S, Mirjalili V. *Python Machine Learning: Machine Learning and Deep Learning with Python, scikit-learn, and TensorFlow 2*. Birmingham: Packt Publishing Ltd., 2019.
100. Pedregosa F, et al. Scikit-learn: machine learning in Python. *The Journal of Machine Learning Research* 2011; 12: 2825–2830.
101. Rajkomar A, et al. Ensuring fairness in machine learning to advance health equity. *Annals of Internal Medicine* 2018; 169: 866–872.
102. Gianfrancesco MA, et al. Potential biases in machine learning algorithms using electronic health record data. *JAMA Internal Medicine* 2018; 178: 1544–1547.
103. Bellamy RK, et al. AI Fairness 360: an extensible toolkit for detecting, understanding, and mitigating unwanted algorithmic bias. arXiv preprint arXiv:181001943, 2018.
104. U.S. Food and Drug Administration (FDA). *2020* [Internet]; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software).
105. Esteva A, et al. A guide to deep learning in healthcare. *Nature Medicine* 2019; 25(1): 24–29.
106. https://deepsense.ai/what-is-reinforcement-learning-the-complete-guide/.
107. Szabo L. Artificial intelligence is rushing into patient care – and could raise risks. *Scientific American and Kaiser Health News* December 24, 2019.
108. https://www.forbes.com/sites/insights-intelai/2019/02/11/can-you-sue-an-algorithm-for-malpractice/#641b557e7013.
109. van der Ploeg T, Austin PC, Steyerberg EW. *Guidelines for reinforcement learning in healthcare*. *AI Fairness 360: an extensible toolkit for detecting, understanding, and mitigating unwanted algorithmic bias.* arXiv preprint arXiv:181001943, 2018.
110. U.S. Food and Drug Administration (FDA). *2020* [Internet]; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software).
111. Ishwaran H, et al. Random survival forests. *The Annals of Applied Statistics* 2008; 2(3): 841–860.
112. Bou-Hamad I, Laroque D, Ben-Ameur H. A review of survival trees. *Statistics Surveys* 2011; 5: 44–71.
113. Graf E, et al. Assessment and comparison of prognostic classification schemes for survival data. *Statistics in Medicine* 1999; 18(17–18): 2529–2545.
114. Zou H, Hastie T. Regularization and variable selection via the elastic net. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* 2005; 67(2): 301–320.
115. Therneau T, Atkinson B. rpart: Recursive Partitioning and Regression Trees. R package version 4.1-15, 2019. (https://CRAN.R-project.org/package=rpart)
116. Hothorn T, Zeileis A. partykit: A modular toolkit for recursive partitioning in R. *The Journal of Machine Learning Research* 2015; 16(1): 3905–3909.